David Windley : Okay. Thank you. The next question is around the capacity expansion change in plans. In the earliest iteration of that Fishers plan and you’ve confirmed this sense, it was about €150 million €“ excuse euro investment that was expected to produce about €150 million in revenue when fully ramped. Can we now expect that this Fishers plant could ramp the €500 million as the revenue, is that’s still kind of the proportion of capacity productivity?
Franco Moro: Yes, I can confirm that it is a reasonable proportion. The nature of the investments is still for high value solutions including more EZ-fill vials, including more syringes, Alba syringes. But the internal rate of return and the success of €“ financial success of the investment is, for us, very important and at the end, yes, you are right that we expect to have the same ratio in between €1 in CapEx, €1 in revenue. These are obviously thumb of rule but this is what we expect.
David Windley : Yes, Franco, thank you. So that segues into the follow-up question on that, which is, roughly, how long would you expect it to take to get to full utilization on that facility thinking both from a revenue standpoint, but then also to the extent that your commentary today suggest that the build to full utilization does have some margin drag to it. How should we think about the time to get to normal margin? So kind of two-parter on that, please.
Marco Dal Lago: The target is that- is multi-year and that we pursue that module-by-moduling in the installation. So we expect it to complete this phase of the investment €500 million by the end of 2026 including the last validation. And then to ramp up we could expect to have at least two years more to have the full utilization of the capacity because that we have to spend time to validate different products and different customers. So, this is the time frame for the full utilization now, but as always our modular approach will allow us some flexibility in terms of possible acceleration or different tuning of the CapEx.
David Windley : Okay. That’s very helpful. Thank you and good luck.
Lisa Miles: Thanks, Dave. Bring the next question please.
Operator: The next question is from Matt Larew of William Blair. Please go ahead.
Madeline Mollman: Hi, this is Madeline Mollman on for Matt Larew. I just want to talk a little bit on the pricing on the supply side, but I just wanted to see how you are thinking about pricing from your perspective in 2023 and as COVID start to roll off, you have opportunities to take price to maybe you are discounting bulk orders, is something like that do you think there is a room for pricing to improve in 2023?
Lisa Miles: Madeline, I apologize. We were unable to hear the beginning of your question and can you please repeat the question and perhaps speak a little for us?
Madeline Mollman: Yes, sorry about that. I was just wondering how you were thinking about pricing in 2023 as COVID begins to roll off if there is going to be opportunities for you to replace large COVID bulk orders that maybe more attractively priced smaller orders, something like that, how you are thinking about pricing in 2023 versus 2022?
Marco Dal Lago: So many time we are €“ we do expect inflation as anybody else in 2023. We are pricing accordingly including in the margin into our pricing. So, we €“ in shifting to our high value solution, this is the products we are keeping with respect to pricing.
Franco Stevanato: On top of that you also remember that COVID business was mostly related to vials. So, we have a much broader range of products and the situation about vials is only part of the true picture for us.
Madeline Mollman: Great. Thank you.
